Shanghai Shyndec Pharmaceutical plans to raise CNY2.03bn ($307.41m) through the private placement of convertible bonds.
The bonds have a maturity period of six years from the issued date.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Headquartered in China, Shanghai Shyndec is a manufacturer of active pharmaceutical ingredients (APIs), chemical raw materials, and finished drug products.
Aprecia Pharmaceuticals has collaborated with Cycle Pharmaceuticals to develop and commercialise ZipDose 3D-printed orphan drugs using the former’s FDA-approved 3DP ZipDose technology platform.
Based in the US, Aprecia Pharmaceuticals is a drug delivery technology company, while Cycle Pharmaceuticals is a UK-based pharmaceutical company.
Japanese pharmaceutical products manufacturer Daiichi Sankyo Company and Puma Biotechnology have signed a pre-clinical research agreement with Memorial Sloan Kettering Cancer Center (MSK).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDaiichi Sankyo’s investigational drug conjugate DS-8201 and Puma Biotech’s tyrosine kinase inhibitor neratinib (NERLYNX) will be investigated in HER2-mutated or HER2-positive solid tumours, as part of the agreement.
Veru has acquired the global rights for oral granule formulation solifenacin from Camargo Pharmaceuticals Services.
Solifenacin is the API in VESIcare, a drug used for treating overactive bladder in men and women.
The acquisition allows Viru to enhance its novel urology drugs portfolio.
